DI VEROLI, AMBRA
 Distribuzione geografica
Continente #
NA - Nord America 3.417
EU - Europa 270
AS - Asia 160
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 3.855
Nazione #
US - Stati Uniti d'America 3.412
IT - Italia 74
SG - Singapore 71
IE - Irlanda 53
CN - Cina 46
UA - Ucraina 44
KR - Corea 28
SE - Svezia 25
DE - Germania 21
GB - Regno Unito 15
FR - Francia 12
RU - Federazione Russa 9
FI - Finlandia 6
HK - Hong Kong 5
JP - Giappone 5
PL - Polonia 5
CA - Canada 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BE - Belgio 2
CO - Colombia 2
CU - Cuba 2
ES - Italia 2
VN - Vietnam 2
AU - Australia 1
BD - Bangladesh 1
IN - India 1
MD - Moldavia 1
NL - Olanda 1
UZ - Uzbekistan 1
Totale 3.855
Città #
Wilmington 1.017
Woodbridge 710
Houston 696
Fairfield 164
Chandler 160
Ashburn 90
Ann Arbor 65
Seattle 60
Singapore 59
New York 52
Cambridge 49
Dublin 47
Medford 32
Rome 29
Dearborn 23
Jacksonville 20
Beijing 17
Lawrence 16
Santa Clara 15
Center 13
Boardman 9
San Diego 9
Menlo Park 8
Moscow 7
Milan 6
Nanjing 5
Redwood City 5
Guangzhou 4
Hackensack 4
London 4
Andong 3
Colorado Springs 3
Hefei 3
Lima 3
Los Angeles 3
Pignola 3
Seoul 3
Shanghai 3
Toronto 3
Zhengzhou 3
Bogotá 2
Brussels 2
Creede 2
Cuneo 2
Dong Ket 2
Engelhard 2
Frankfurt am Main 2
Fuzhou 2
Havana 2
Hong Kong 2
Kraków 2
Norwalk 2
Pomezia 2
Siena 2
Verona 2
Warsaw 2
Atlanta 1
Auburn Hills 1
Bari 1
Caserta 1
Central 1
Changsha 1
Chisinau 1
Chiswick 1
Clearwater 1
Council Bluffs 1
Dhaka 1
Dothan 1
Falls Church 1
Guidonia 1
Hangzhou 1
Hounslow 1
Kilburn 1
Kunming 1
Kyiv 1
Lappeenranta 1
Las Vegas 1
Madrid 1
Milazzo 1
Monte Vista 1
Munich 1
New Bedfont 1
Padova 1
Paris 1
Pescia 1
Philadelphia 1
Phoenix 1
Putian 1
Redmond 1
Shenyang 1
Sydney 1
Tappahannock 1
Torino 1
Trieste 1
University Park 1
Wenzhou 1
Zgierz 1
Zhangzhou 1
Totale 3.499
Nome #
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 384
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 371
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 349
Treatment of low-blast count AML using hypomethylating agents 346
Reversible hyporegenerative anemia during natalizumab treatment 342
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 306
Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients 278
Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes 273
The emerging role of measurable residual disease detection in AML in morphologic remission 246
Cytotoxicity and differentiating effect of the poly(ADP-ribose) polymerase inhibitor olaparib in myelodysplastic syndromes 245
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 227
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations 156
Quality-of-life monitoring during hematopoietic stem cell transplantation: observations and a suggestion from the rome transplant network quality of life working party 139
Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN 79
Diabetic retinopathy and age-related macular degeneration: A survey of pharmacoutilization and cost in Calabria, Italy 56
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia 56
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide 50
The emerging role of measurable residual disease detection in AML in morphologic remission 25
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience 25
Totale 3.953
Categoria #
all - tutte 9.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.844


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020808 0 0 0 87 83 92 111 98 87 92 82 76
2020/2021829 80 87 79 91 132 93 89 87 18 34 28 11
2021/2022190 10 12 15 5 3 25 9 16 3 20 14 58
2022/2023380 36 34 39 36 31 63 61 23 36 8 4 9
2023/2024159 19 9 9 4 10 57 2 5 1 2 5 36
2024/202598 9 54 29 6 0 0 0 0 0 0 0 0
Totale 3.953